Mendes Rodrigo E, Hogan Patricia A, Streit Jennifer M, Jones Ronald N, Flamm Robert K
JMI Laboratories, North Liberty, Iowa, USA
Pfizer Inc., Collegeville, Pennsylvania, USA.
Antimicrob Agents Chemother. 2015 Apr;59(4):2454-7. doi: 10.1128/AAC.04784-14. Epub 2015 Feb 2.
Linezolid showed MIC50s and MIC90s of 1 μg/ml (for both) against Staphylococcus aureus. Two S. aureus strains exhibited higher MICs (4 to 8 μg/ml) caused by cfr and/or target site mutations, including the first detection of cfr in Poland. Linezolid (MIC50 and MIC90, 0.5 and 1 μg/ml) had potent MICs against coagulase-negative staphylococci (CoNS). Four CoNS had MICs of 16 to 128 μg/ml due to alterations in 23S rRNA and/or L3/L4. Linezolid inhibited all enterococci and streptococci at ≤2 μg/ml, except for one Enterococcus faecium strain (MIC, 8 μg/ml; G2576T [Escherichia coli numbering] mutation).
利奈唑胺对金黄色葡萄球菌的 MIC50 和 MIC90 均为 1 μg/ml。两株金黄色葡萄球菌菌株因 cfr 和/或靶点位点突变而表现出较高的 MIC（4 至 8 μg/ml），包括在波兰首次检测到的 cfr。利奈唑胺对凝固酶阴性葡萄球菌（CoNS）具有强效 MIC（MIC50 和 MIC90 分别为 0.5 和 1 μg/ml）。四株 CoNS 因 23S rRNA 和/或 L3/L4 改变而 MIC 为 16 至 128 μg/ml。利奈唑胺对所有肠球菌和链球菌的抑制浓度≤2 μg/ml，但有一株粪肠球菌菌株除外（MIC 为 8 μg/ml；G2576T [大肠杆菌编号] 突变）。
